A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors

OBJECTIVES: SLC-0111 is an ureido-substituted benzenesulfonamide small molecule inhibitor of carbonic anhydrase IX. The objectives of this first-in-human Phase 1 study were to determine the safety and tolerability of SLC-0111 in patients with advanced solid tumors and to establish the recommended Ph...

Descripción completa

Detalles Bibliográficos
Autores principales: McDonald, Paul C., Chia, Stephen, Bedard, Philippe L., Chu, Quincy, Lyle, Michael, Tang, Liren, Singh, Madhu, Zhang, Zaihui, Supuran, Claudiu T., Renouf, Daniel J., Dedhar, Shoukat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Articles: Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323835/
https://www.ncbi.nlm.nih.gov/pubmed/32251122
http://dx.doi.org/10.1097/COC.0000000000000691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323835/
https://www.ncbi.nlm.nih.gov/pubmed/32251122
http://dx.doi.org/10.1097/COC.0000000000000691

Ejemplares similares